[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].
Identifieur interne : 000052 ( an2020/Analysis ); précédent : 000051; suivant : 000053[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].
Auteurs :Source :
- Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases [ 1001-0939 ] ; 2020.
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs.
DOI: 10.3760/cma.j.cn112147-20200221-00138
PubMed: 32125132
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000323
- to stream PubMed, to step Curation: 000323
- to stream PubMed, to step Checkpoint: 000046
- to stream Ncbi, to step Merge: 000A89
- to stream Ncbi, to step Curation: 000A89
- to stream Ncbi, to step Checkpoint: 000A89
- to stream Main, to step Merge: 000054
- to stream Main, to step Curation: 000052
- to stream Main, to step Exploration: 000052
- to stream an2020, to step Extraction: 000052
Links to Exploration step
pubmed:32125132Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].</title></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32125132</idno><idno type="pmid">32125132</idno><idno type="doi">10.3760/cma.j.cn112147-20200221-00138</idno><idno type="wicri:Area/PubMed/Corpus">000323</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000323</idno><idno type="wicri:Area/PubMed/Curation">000323</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000323</idno><idno type="wicri:Area/PubMed/Checkpoint">000046</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000046</idno><idno type="wicri:Area/Ncbi/Merge">000A89</idno><idno type="wicri:Area/Ncbi/Curation">000A89</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A89</idno><idno type="wicri:Area/Main/Merge">000054</idno><idno type="wicri:Area/Main/Curation">000052</idno><idno type="wicri:Area/Main/Exploration">000052</idno><idno type="wicri:Area/an2020/Extraction">000052</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].</title></analytic><series><title level="j">Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</title><idno type="ISSN">1001-0939</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs.</div></front></TEI><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/an2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000052 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd -nk 000052 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= an2020
|étape= Analysis
|type= RBID
|clé= pubmed:32125132
|texte= [Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/an2020/Analysis/RBID.i -Sk "pubmed:32125132" \
| HfdSelect -Kh $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |